Suppr超能文献

基于分子动力学模拟和结合能计算研究 HIV-1 蛋白酶 M46I 突变诱导的沙奎那韦耐药的耐药机制。

Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation.

机构信息

Molecular Signaling & Drug Discovery Laboratory, Department of Biochemistry, Central University of Punjab, Bathinda 151401, Punjab, India.

Department of Urology, Pharmacology and Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.

出版信息

Viruses. 2022 Mar 28;14(4):697. doi: 10.3390/v14040697.

Abstract

Drug-resistance-associated mutation in essential proteins of the viral life cycle is a major concern in anti-retroviral therapy. M46I, a non-active site mutation in HIV-1 protease has been clinically associated with saquinavir resistance in HIV patients. A 100 ns molecular dynamics (MD) simulation and MM-PBSA calculations were performed to study the molecular mechanism of M46I-mutation-based saquinavir resistance. In order to acquire deeper insight into the drug-resistance mechanism, the flap curling, closed/semi-open/open conformations, and active site compactness were studied. The M46I mutation significantly affects the energetics and conformational stability of HIV-1 protease in terms of RMSD, RMSF, Rg, SASA, and hydrogen formation potential. This mutation significantly decreased van der Waals interaction and binding free energy (∆G) in the M46I-saquinavir complex and induced inward flap curling and a wider opening of the flaps for most of the MD simulation period. The predominant open conformation was reduced, but inward flap curling/active site compactness was increased in the presence of saquinavir in M46I HIV-1 protease. In conclusion, the M46I mutation induced structural dynamics changes that weaken the protease grip on saquinavir without distorting the active site of the protein. The produced information may be utilized for the discovery of inhibitor(s) against drug-resistant HIV-1 protease.

摘要

耐药相关突变在病毒生命周期的必需蛋白中是抗逆转录病毒治疗的主要关注点。HIV-1 蛋白酶中的非活性部位突变 M46I 已在临床上与 HIV 患者的沙奎那韦耐药相关。进行了 100ns 的分子动力学(MD)模拟和 MM-PBSA 计算,以研究基于 M46I 突变的沙奎那韦耐药的分子机制。为了更深入地了解耐药机制,研究了瓣卷曲、闭合/半开/打开构象以及活性部位紧凑性。M46I 突变在 RMSD、RMSF、Rg、SASA 和氢键形成潜力方面,对 HIV-1 蛋白酶的能量和构象稳定性有显著影响。该突变显著降低了 M46I-沙奎那韦复合物中范德华相互作用和结合自由能(∆G),并在大多数 MD 模拟期间诱导瓣向内卷曲和瓣更宽的打开。主要的开放构象减少,但在 M46I HIV-1 蛋白酶中存在沙奎那韦时,瓣向内卷曲/活性部位紧凑性增加。总之,M46I 突变诱导的结构动力学变化削弱了蛋白酶对沙奎那韦的抓握,而不会扭曲蛋白质的活性部位。所产生的信息可用于发现针对耐药 HIV-1 蛋白酶的抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04df/9031992/0ad23ec8a911/viruses-14-00697-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验